TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells

The human leukocyte antigen (HLA; also called major histocompatibility, or MHC) class I system presents peptides that distinguish healthy from diseased cells. Therefore, the discovery of peptide/MHC class I markers can provide highly specific targets for immunotherapy. Over the course of almost two...

Full description

Saved in:
Bibliographic Details
Published in:International Reviews of Immunology 2011-10, Vol.30 (5-6), p.328-340
Main Authors: Weidanz, Jon A., Hawkins, Oriana, Verma, Bhavna, Hildebrand, William H.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - immunology
Cell Line
Cell Line, Tumor
Epitopes, T-Lymphocyte - immunology
Histocompatibility Antigens Class I - immunology
Histocompatibility Antigens Class I - metabolism
Humans
Immunotherapy - methods
peptide epitope discovery, peptide/MHC class I complexes, peptide/HLA complexes, TCRm, monoclonal antibodies, TCR-like monoclonal antibodies
Peptides - immunology
Peptides - metabolism
Receptors, Antigen, T-Cell - immunology
Receptors, Antigen, T-Cell - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The human leukocyte antigen (HLA; also called major histocompatibility, or MHC) class I system presents peptides that distinguish healthy from diseased cells. Therefore, the discovery of peptide/MHC class I markers can provide highly specific targets for immunotherapy. Over the course of almost two decades, various strategies have been used, with mixed success, to produce antibodies that have recognition specificity for unique peptide/MHC class I complexes that mark infected and cancerous cells. Using these antibody reagents, novel peptide/MHC class I targets have been directly validated on diseased cells and new insight has been gained into the mechanisms of antigen presentation. More recently, these antibodies have shown promise for clinical applications such as therapeutic targeting of cancerous and infected cells and diagnosis and imaging of diseased cells. In this review, the authors comprehensively describe the methods used to identify disease-specific peptide/MHC class I epitopes and generate antibodies to these markers. Finally, they offer several examples that illustrate the promise of using these antibodies as anti-cancer agents.
ISSN:0883-0185
1937-4364
1563-5244
DOI:10.3109/08830185.2011.604880